¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2020³â Ç¥ÀûÄ¡·á¿¬±¸È¸ Ãá°è½ÉÆ÷Áö¾ö : 2020-03-28

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
2020³â Ç¥ÀûÄ¡·á¿¬±¸È¸ Ãá°è½ÉÆ÷Áö¾ö : 2020-03-28
±³À°ÀÏÀÚ : 2020-03-28
±³À°Àå¼Ò : ºÎ»ê º¤½ºÄÚ Á¦2 Àü½ÃÀå  
±³À°ÁÖÁ¦ : 2020³â Ç¥ÀûÄ¡·á¿¬±¸È¸ Ãá°è½ÉÆ÷Áö¾ö
ÁÖÃÖ±â°ü : ´ëÇÑÆó¾ÏÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : Ç¥ÀûÄ¡·á¿¬±¸È¸  
´ã´çÀÚ : ½É¹Î°æ
¿¬¶ôó : 02-741-8540  
À̸ÞÀÏ : kalc@lungca.or.kr      
±³À°Á¾·ù : ³»°ú, ¿Ü°ú, ÈäºÎ¿Ü°ú, ¹æ»ç¼±Á¾¾çÇаú, º´¸®°ú, ÇÙÀÇÇаú      
Âü¼®¿¹»óÀοø : 100¸í
Èñ¸ÁÆòÁ¡ : 3Á¡  
Áö¿ª : ºÎ»ê±¤¿ª½Ã
±³À°½Ã°£ : 3 ½Ã°£ 50ºÐ  
¼¼ºÎ¼ö°­·á : 80,000¿ø      
ºñ°í È¸¿ø - »çÀüµî·Ï 50,000¿ø, ÇöÀåµî·Ï 60,000¿øºñȸ¿ø »çÀüµî·Ï 70,000¿ø ÇöÀåµî·Ï 80,000¿ø      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 03-28 º¤½ºÄÚ Á¦2Àü½ÃÀå 12:00~12:40 Nivolumab, 5 year OS outcome of CheckMate 017/057 and real world outcome in Korea  ±è¹ÌÇö(ºÎ»êÀÇ´ë) 
È޽Ġ03-28 º¤½ºÄÚ Á¦2Àü½ÃÀå 12:40~13:00 È޽Ġ () 
±³À°½Ã°£ 03-28 º¤½ºÄÚ Á¦2Àü½ÃÀå 13:00~13:20 Hyperprogression or pseudoprogression in immune checkpoint inhibitor treatment, that is the question  ¹Úö±Ô(Àü³²ÀÇ´ë) 
±³À°½Ã°£ 03-28 º¤½ºÄÚ Á¦2Àü½ÃÀå 13:20~13:40 Updates of clinical and biomarkers for immune check point inhibitors treating NSCLC  À¯½Â¼ö(°æºÏÀÇ´ë) 
±³À°½Ã°£ 03-28 º¤½ºÄÚ Á¦2Àü½ÃÀå 13:40~14:00 Drug agonistic acquired resistance in target therapy, is that a clue for outcome improvement?  À±¼ºÈÆ(ºÎ»êÀÇ´ë) 
±³À°½Ã°£ 03-28 º¤½ºÄÚ Á¦2Àü½ÃÀå 14:00~14:20 Sequential treatment issues of target therapy in EGFR or ALK+ NSCLC  À̽ÂÇö(°æÈñÀÇ´ë) 
Åä·Ð 03-28 º¤½ºÄÚ Á¦2Àü½ÃÀå 14:20~14:30 Åä·Ð  () 
È޽Ġ03-28 º¤½ºÄÚ Á¦2Àü½ÃÀå 14:30~15:00 È޽Ġ () 
±³À°½Ã°£ 03-28 º¤½ºÄÚ Á¦2Àü½ÃÀå 15:00~15:20 Pathogenesis, clinicopathologic feature, and diagnosis of NTRK fusion+ NSCLC  ±èÅÂÁ¤(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 03-28 º¤½ºÄÚ Á¦2Àü½ÃÀå 15:20~15:40 Treatment of NTRK fusion+ NSCLC  À̸í±Ô(¿¬¼¼ÀÇ´ë) 
Åä·Ð 03-28 º¤½ºÄÚ Á¦2Àü½ÃÀå 15:40~15:50 Åä·Ð  () 
±³À°½Ã°£ 03-28 º¤½ºÄÚ Á¦2Àü½ÃÀå 15:50~16:10 Emerging target agents for KRAS+ NSCLC  ±èÀξÖ(°Ç±¹ÀÇ´ë) 
±³À°½Ã°£ 03-28 º¤½ºÄÚ Á¦2Àü½ÃÀå 16:10~16:30 Efficacy of immune check point inhibitors for KRAS+ NSCLC  ¹ÚÁö¿µ(ÇѸ²ÀÇ´ë) 
Åä·Ð 03-28  16:30~16:40 Åä·Ð  () 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2020³â Ç¥ÀûÄ¡·á¿¬±¸È¸ Ãá°è½ÉÆ÷Áö¾ö : 2020-03-28""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û 2020³âµµ Á¦4ȸ ȯ°æ¼º ÆóÁúȯ ¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2020-03-28
´ÙÀ½±Û ¼­¿ï´ëÇб³º´¿ø Ç÷¾×Á¾¾ç³»°úÀÇ ÃÖ½ÅÁö°ß 2020 : 2020-03-28
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20467 ¼­¿ï 2024 ´ëÇÑÇ÷¾×ÇÐȸ Á¶Á÷±¸Áõ½ÄÁõ¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2024-05-31 0 75 2024-04-17
20466 °æ±â ¾ÆÁִ뺴¿ø ÀÀ±ÞÀÇÇаú ¼³¸³ 30Áֳ⠱â³ä ½ÉÆ÷Áö¿ò : 2024-05-30 0 37 2024-04-17
20465 ¼­¿ï Á¦20Â÷ ´ëÇѸð¹ßÇÐȸ Çмú´ëȸ ÇÁ·Î±×·¥ : 2024-05-26 0 45 2024-04-17
20464 °æ±â 2024³â Á¦86Â÷ ´ëÇÑ»ý½ÄÀÇÇÐȸ Ãá°èÇмú´ëȸ : 2024-05-26 0 29 2024-04-17
20463 ¼­¿ï 2024³â ´ëÇѼҾƼÒÈ­±â¿µ¾çÇÐȸ Ãá°è ½ÉÆ÷Áö¾ö : 2024-05-26 0 19 2024-04-17
20462 ¼­¿ï ´ëÇÑÃæ°ÝÆÄÄ¡·áÇÐȸ 2024 Ãá°è Çмú´ëȸ : 2024-05-26 0 20 2024-04-17
20461 ¼­¿ï Áø´Ü ü°èÀû¹®Çå°íÂû ¿öÅ©¼¥ : 2024-05-25 0 28 2024-04-17
20460 ¼­¿ï ´ëÇѺñ¸¸ÇÐȸ Á¦17ȸ ODOT (One Day Course of Obesity Treatment) : 2024-05-25 0 19 2024-04-17
20459 ¼­¿ï 2024³â Á¾¾ç¸é¿ª´ÙÇÐÁ¦¿¬±¸È¸ Ãá°è½ÉÆ÷Áö¾ö : 2024-05-24 0 14 2024-04-17
20458 ¼­¿ï 2024 Á¦12ȸ ´ëÇÑÇ÷¾×ÇÐȸ Ç÷¿ìº´¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2024-05-24 0 25 2024-04-17
20457 ¼­¿ï 2024³â ¿µµîÆ÷±¸ÀÇ»çȸ Ãá°è Çмú´ëȸ : 2024-05-21 0 30 2024-04-17
20456 ¼­¿ï 2024³â ´ëÇÑÀÓ»ó°Ç°­ÁõÁøÇÐȸ Ãá°èÇмú´ëȸ ¹× ¿¬¼ö°­Á : 2024-05-19 0 29 2024-04-17
20455 ¼­¿ï Á¦7Â÷ ´ëÇѼö¸éÈ£ÈíÇÐȸ Ãá°èÇмú´ëȸ : 2024-05-19 0 38 2024-04-17
20454 ¼­¿ï 2024 ´ëÇѼҾÆÇ÷¾×Á¾¾çÇÐȸ Ãá°è¿¬¼ö°­Á : 2024-05-18 0 26 2024-04-17
20453 ¼­¿ï 2024³â ´ëÇÑ¿¬ÇÏÀå¾ÖÇÐȸ Á¦14ȸ Ãá°èÇмú´ëȸ : 2024-05-18 0 29 2024-04-17
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷